FLT3 and acute myeloid leukemia: Among proteins relevant to non-CBF, the overexpression of TESC also shown to be highly expressed in FLT3-ITD(+) AML mediating sorafenib resistance [38], suggesting potential drug resistance in non-CBF AML.